Top Markets
Coin of the day
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
株式のランク #17992
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
株価
$1.69
最終同期: 2026-09-02
時価総額
$216.83M
変化(1日)
3.38%
変化(1年)
-66.03%
US
取引 Organogenesis Holdings Inc. (ORGO)

カテゴリー

Bの時価総額のORGOの価格
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
ORGO
$1.69
の時価総額 Organogenesis Holdings Inc.(ORGO)
時価総額: $216.83M
September 2026時点で、Organogenesis Holdings Inc. の時価総額は $216.83M です。これは、当社のデータによると、Organogenesis Holdings Inc. が世界で17992nd番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Organogenesis Holdings Inc. の時価総額の履歴(2017 から 2026 まで)
ORGO最も人気のあるトップ5と比較stocks
ORGOの価格 資産b bの市場 結果
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$42,155.14 $216.83M
$5.424T +2,501,539.97%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$37,116.02 $216.83M
$4.776T +2,202,500.65%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$31,488.85 $216.83M
$4.052T +1,868,563.68%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$28,685.07 $216.83M
$3.691T +1,702,177.25%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$21,327.01 $216.83M
$2.744T +1,265,523.00%